COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

•Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies.•These challenges fall under three dimensions – vaccine development, dissemination, and deployment.•Decision...

Full description

Saved in:
Bibliographic Details
Published in:Health policy (Amsterdam) Vol. 125; no. 5; pp. 553 - 567
Main Authors: Forman, Rebecca, Shah, Soleil, Jeurissen, Patrick, Jit, Mark, Mossialos, Elias
Format: Journal Article
Language:English
Published: Ireland Elsevier B.V 01.05.2021
Elsevier Science Ltd
The Author(s). Published by Elsevier B.V
Subjects:
Authorization
Campaigns
Candidates
Challenges
Clinical research
Clinical trials
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
Decision makers
Dissemination
Ethics
Humans
Immunity
Immunization
Internal Medicine
Pandemics
R&D
Research & development
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Surveillance
Uptake
Vaccines
ISSN:0168-8510, 1872-6054, 1872-6054
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies.•These challenges fall under three dimensions – vaccine development, dissemination, and deployment.•Decision-makers can anticipate and recognize these challenges, and strategize solutions at scale.•Effective vaccines can add to our existing arsenal of weapons against COVID-19. Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0168-8510
1872-6054
1872-6054
DOI:10.1016/j.healthpol.2021.03.013